Theseus Pharmaceuticals Inc

NASDAQ THRX

Data sourced from

and

Daily

Download Data

Theseus Pharmaceuticals Inc Enterprise Value to EBITDA (EV/EBITDA) on February 23, 2024

Theseus Pharmaceuticals Inc Enterprise Value to EBITDA (EV/EBITDA) is NA on February 23, 2024, a NA change year over year. The EV/EBITDA ratio compares a company's enterprise value to its EBITDA. It provides insight into the company's valuation relative to its earnings and is commonly used in comparing the relative value of different companies within an industry. A lower ratio suggests a potentially more favorable valuation.

Theseus Pharmaceuticals Inc 52-week high Enterprise Value to EBITDA (EV/EBITDA) is NA on February 23, 2024, which is NA below the current Enterprise Value to EBITDA (EV/EBITDA).
Theseus Pharmaceuticals Inc 52-week low Enterprise Value to EBITDA (EV/EBITDA) is NA on February 23, 2024, which is NA below the current Enterprise Value to EBITDA (EV/EBITDA).
Theseus Pharmaceuticals Inc average Enterprise Value to EBITDA (EV/EBITDA) for the last 52 weeks is NA.

NASDAQ: THRX

Theseus Pharmaceuticals Inc

CEO	Dr. Iain D. Dukes D.Phil., DPHIL, M.A.
IPO Date	Oct. 7, 2021
Location	United States
Headquarters	245 Main Street, Cambridge, MA, United States, 02142
Employees	38
Sector	Healthcare
Industry	Biotechnology

Description

Theseus Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of targeted therapies for the treatment of cancer patients. Its lead product candidate is THE-630, a pan-KIT inhibitor for the treatment of gastrointestinal stromal tumors. The company also develops THE-349, a fourth-generation selective epidermal growth factor receptor inhibitor to address C797X-mediated resistance to first- or later-line osimertinib treatment in patients with non-small cell lung cancer. Its development programs address drug resistance mutations in key driver oncogenes, which are mutated genes that cause cancer. The company was incorporated in 2017 and is based in Cambridge, Massachusetts. As of February 14, 2024, Theseus Pharmaceuticals, Inc. operates as a subsidiary of Concentra Biosciences, LLC.

Key trends